NVRO vs. CERS, LUNG, SKIN, ANIK, TCMD, OSUR, GUTS, TMCI, PLSE, and TLSI Should you be buying Nevro stock or one of its competitors? The main competitors of Nevro include Cerus (CERS), Pulmonx (LUNG), Beauty Health (SKIN), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Fractyl Health (GUTS), Treace Medical Concepts (TMCI), Pulse Biosciences (PLSE), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry.
Nevro (NYSE:NVRO ) and Cerus (NASDAQ:CERS ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
95.5% of Nevro shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 3.2% of Nevro shares are held by insiders. Comparatively, 7.1% of Cerus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cerus has lower revenue, but higher earnings than Nevro. Cerus is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
Nevro presently has a consensus price target of $20.00, indicating a potential upside of 75.44%. Cerus has a consensus price target of $3.83, indicating a potential upside of 94.59%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than Nevro.
Nevro has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
In the previous week, Cerus had 1 more articles in the media than Nevro. MarketBeat recorded 2 mentions for Cerus and 1 mentions for Nevro. Cerus' average media sentiment score of 0.80 beat Nevro's score of -0.10 indicating that Cerus is being referred to more favorably in the news media.
Cerus received 65 more outperform votes than Nevro when rated by MarketBeat users. Likewise, 72.26% of users gave Cerus an outperform vote while only 65.84% of users gave Nevro an outperform vote.
Nevro has a net margin of -19.17% compared to Cerus' net margin of -19.27%. Nevro's return on equity of -27.48% beat Cerus' return on equity.
Summary Cerus beats Nevro on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
